While most of our results align with existing studies, the unique identification of mutations such as SAMD9L and ATP8B1 in metastatic tumors and gender-specific enrichment of CDK8 and EPHB2 are less commonly reported and may represent new areas for investigation in personalized therapeutics. Here, SAMD9L is linked to metastatic neoplasm.